Previous 10 | Next 10 |
Six-month stability data remain more than 10x below the acceptable intake limit set by the U.S. Food and Drug Administration (FDA) and continue to support the requested product shelf life Submission of six-month stability data satisfies Phathom's stability data submission requirements for...
2023-08-10 12:23:37 ET Phathom Pharmaceuticals press release ( NASDAQ: PHAT ): Q2 GAAP EPS of -$0.84 beats by $0.14 . As of June 30, 2023, cash and cash equivalents were $248.8 million. For further details see: Phathom Pharmaceuticals GAAP EPS of -$0.84 beats...
Prior Approval Supplement (PAS) for VOQUEZNA ® TRIPLE PAK ® and VOQUEZNA ® DUAL PAK ® assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 30, 2023 by the U.S. Food and Drug Administration (FDA) U.S. commercial launch for H. pylori ...
2023-08-07 14:34:09 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the safest sectors on the market is biotech. After all, we can’t stop people from aging — at least not yet. We have millions of people retiring and demanding better care. T...
2023-07-14 16:12:22 ET Summary Phathom Pharmaceuticals, Inc. is trading near 52-week highs. Despite its potential, there are reasons, like a competitive market, why we should take profits on Phathom Pharmaceuticals. If it falls back without major negative reasons before approv...
Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023 Combined launch of vonoprazan for Erosive GERD and H. pylori indications planned for Q4 2023, if approved FLORHAM PARK, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...
FLORHAM PARK, N.J., June 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the closing of the sale of an additional 1,668,750 shares of co...
2023-05-24 05:04:27 ET Biopharmaceutical company, Phathom Pharmaceuticals ( NASDAQ: PHAT ) slides 8% as it prices ~11.13M shares at a price to the public of $11.75 per share. The gross proceeds are expected to be ~$130.7M. Underwriters have a 30-day option to purch...
2023-05-23 17:37:45 ET Phathom Pharmaceuticals ( NASDAQ: PHAT ) on Tuesday said it had resubmitted its new drug application (NDA) for its acid suppressant vonoprazan to the U.S. Food and Drug Administration (FDA). The company resubmitted the vonoprazan NDA for the trea...
2023-05-23 17:14:55 ET Gainers: Reata Pharmaceuticals ( RETA ) +10% . Urban Outfitters ( URBN ) +7% . COMPASS Pathways ( CMPS ) +6% . Stitch Fix ( SFIX ) +5% . TScan Therapeutics ( TCRX ) +4% . Losers: PTC The...
News, Short Squeeze, Breakout and More Instantly...
Phathom Pharmaceuticals Inc. Company Name:
PHAT Stock Symbol:
NYSE Market:
Phathom Pharmaceuticals Inc. Website:
VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD) VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment VOQUEZNA repre...
2024-06-23 22:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...